The abstract is read at the publisher; the summary is JClub's.
In 287,145 localized prostate cancer patients, Decipher reclassified 21% of NCCN low/favorable intermediate cases as high risk and 33% of NCCN high-risk cases as GC-lower risk.
- Why it matters: Clinical and genomic risk groups can disagree, and the molecular features behind that discordance are unclear, limiting more precise long-term prognostic stratification after treatment.
- What they did: Using biopsy data, the study quantified four adverse molecular features—TP53 mutant-like status, PTEN inactivation, lower AR activity, and RB1 loss—across Decipher Genomic Classifier and NCCN risk groups, then assessed distant metastasis in 15,109 NCCN high/very high-risk patients.
- The result: A high Decipher GC score predicted distant metastasis, and AMFs independently predicted distant metastasis; with at least one AMF plus GC score >0.60, the predicted 5-year DM probability was 17–25% versus 5% for favorable molecular profiles with GC score ≤0.60.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.